Dr. Jacqueline Lui, President of Eagle IP Group, chaired a panel discussion titled “Intellectual Property Protection In Life Science” at the Hong Kong Biotech Horizon 2017: Global Congress on Biotechnology: Diagnostics and Therapeutics.
Our Past Events
Recommended Insights
China Provides Specific Directions to Strengthen Patent / Technology Protection from 2020 to 2021
23 April 2020China continues to progress towards its major goal of significantly strengthening IP protection within its borders. Last year it announced several proposed amendments to its patent laws. In January 2020 China and the US signed the Economic and Trade Agreement between the Government of China and US (published 16 January 2020 –“Trade Agreement”), which detailed […]
Read more >
China Top 50 Case of 2019: How a Functional Feature is Construed Greatly Impacts Protection Scope - Shimano KK v. SENSAH
20 July 2020Every year in the spring The Supreme People’s Court of PRC announces its “Top 10 Intellectual Property (IP) cases” and “50 typical IP cases in Chinese courts” of the year. Although not having precedential weight, these cases serve as a reference and guide people's courts at all levels regarding their intellectual property trials. It’s always […]
Read more >
US vs CN: Foreign Filing License Requirements
9 November 2022In China, foreign filing requirements are generally very similar to the US — a foreign filing license is required if a foreign application is to be filed first for an invention made in the country. The Chinese equivalent to the US foreign filing license is called a confidentiality examination for foreign filing. According to Chinese […]
Read more >
China Releases Draft Implementation Guidelines for the Drug Administration Law
2 June 2022The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]
Read more >